NanoPin Technologies

NanoPin Technologies, founded in 2017 and headquartered in San Diego, is a private diagnostics company pioneering a nanoparticle-based platform for infectious disease detection. Its core innovation involves proprietary antibody-conjugated nanoparticles that bind to disease-specific antigen peptides present only during active infection, enabling sensitive blood-based diagnosis. The company's lead efforts target the global tuberculosis epidemic, with assays also developed for HIV and COVID-19, and it has established a key collaboration with Thermo Fisher Scientific. NanoPin operates in the Laboratory Developed Test (LDT) market while advancing its platform for broader applications.

Proprietary diagnostic platform using antibody-conjugated nanoparticles to detect disease-specific antigen peptides present only during active infection in blood samples. Enables rapid, sensitive, and specific distinction between latent and active disease.

NanoPin competes with established TB diagnostics like sputum smear microscopy, culture, and molecular tests (e.g., Cepheid's GeneXpert). Its key differentiators are the use of blood samples, detection of active (vs. latent) disease, and high sensitivity in difficult patient populations. It also faces competition from other companies developing novel biomarker-based and point-of-care TB tests.